R. M. Bernardi

Suggest Changes
Learn More
PURPOSE Retinoic acid-arsenic trioxide (ATRA-ATO) combination therapy is the current standard of care for patients with acute promyelocytic leukemia (APL) carrying the oncogenic fusion protein(More)